Adalimumab/Humira® (Abbott, IL, USA) and golimumab/Simponi® (Janssen Biotech Inc.) are human IgG1-κ light-chain mAbs directed against TNF-α. They have been selected by phage display ...

Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade ... 12 weeks of therapy with adalimumab.

has now shown that acquired resistance to anti-TNF therapies differs between agents. The study included 1,198 patients with RA, treated with infliximab, etanercept or adalimumab, identified from ...

In parallel, experiments performed by the study team also found that the specific protein that adalimumab inhibits, called tumor necrosis factor (TNF), , was potentially playing a key role in iMCD.

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

In parallel, experiments performed by the study team also found that the specific protein that adalimumab inhibits, called tumor necrosis factor (TNF), , was potentially playing a key role in iMCD.

In parallel, experiments performed by the study team also found that the specific protein that adalimumab inhibits, called tumor necrosis factor (TNF), , was potentially playing a key role in iMCD.